Literature DB >> 3707629

Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

A M Stupi, V D Steen, G R Owens, E L Barnes, G P Rodnan, T A Medsger.   

Abstract

Pulmonary hypertension (PHT) occurred in 59 (9%) of 673 systemic sclerosis patients seen between 1963 and 1983. In 30 patients, all with the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), the pulmonary hypertension was isolated, i.e., independent of other pulmonary or cardiac conditions. In 20 patients, isolated PHT was demonstrated by cardiac catheterization. All had normal or only mildly decreased lung volumes, and mild or no pulmonary interstitial fibrosis on chest roentgenogram. In comparison with 287 CREST syndrome patients without PHT, these 20 patients had markedly reduced diffusing capacity for carbon monoxide (DLCO) (mean 39% of predicted normal). In 6 patients, the low DLCO antedated clinical evidence of PHT by 1-6 years. At autopsy there was marked intimal fibrosis with hyalinization and smooth muscle hypertrophy in the small- and medium-sized arteries, without significant parenchymal fibrosis or inflammation. Patients with isolated PHT did not respond favorably to vasodilators and had a very poor prognosis, with a 2-year cumulative survival rate of 40%. A DLCO less than 45% of predicted in the absence of pulmonary interstitial fibrosis may be an important predictor of the subsequent development of isolated PHT.

Entities:  

Mesh:

Year:  1986        PMID: 3707629     DOI: 10.1002/art.1780290409

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  57 in total

1.  Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension.

Authors:  R J Stratton; L Pompon; J G Coghlan; J D Pearson; C M Black
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

Review 2.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

3.  Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.

Authors:  John Varga
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.592

Review 4.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

5.  Predictors of end stage lung disease in systemic sclerosis.

Authors:  V Steen
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

6.  Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry.

Authors:  Sangmee Bae; Rajeev Saggar; Marcy B Bolster; Lorinda Chung; Mary Ellen Csuka; Chris Derk; Robyn Domsic; Aryeh Fischer; Tracy Frech; Avram Goldberg; Monique Hinchcliff; Vivien Hsu; Laura Hummers; Elena Schiopu; Maureen D Mayes; Vallerie McLaughlin; Jerry Molitor; Nausheen Naz; Daniel E Furst; Paul Maranian; Virginia Steen; Dinesh Khanna
Journal:  Ann Rheum Dis       Date:  2012-02-02       Impact factor: 19.103

7.  Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.

Authors:  Dinesh Khanna; Heather Gladue; Richard Channick; Lorinda Chung; Oliver Distler; Daniel E Furst; Eric Hachulla; Marc Humbert; David Langleben; Stephen C Mathai; Rajeev Saggar; Scott Visovatti; Nezam Altorok; Whitney Townsend; John FitzGerald; Vallerie V McLaughlin
Journal:  Arthritis Rheum       Date:  2013-12

8.  Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  Reda E Girgis; Adaani E Frost; Nicholas S Hill; Evelyn M Horn; David Langleben; Vallerie V McLaughlin; Ronald J Oudiz; Ivan M Robbins; James R Seibold; Shelley Shapiro; Victor F Tapson; Robyn J Barst
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

Review 9.  [Systemic sclerosis. Objectives for the treatment].

Authors:  B Maurer; M Walder; R E Gay; S Gay; O Distler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

Review 10.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.